ETCTN A phase 1 trial of MLN0128 (TAK-228) in combination with osimertinib (AZD9291) in advanced EGFR mutation positive non-small cell lung cancer (NSCLC) after progression on a previous EGFR tyrosine kinase inhibitor Adult CIRB - Early Phase Emphasis Active Available to Open